|
| Wednesday, February 22, 2023 |
|
|
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration |
| Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced that two of its wholly-owned subsidiaries, Essex Bio-Investment Limited ("Essex Bio-Investment") and Zhuhai Essex Bio-Pharmaceutical Co. Ltd ("Zhuhai Essex") more info >> |
|
| Friday, February 10, 2023 |
|
|
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases |
| Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced that the first patient in the United States (US) was dosed in a global multi-centre phase 3 clinical trial (NCT04740671) of EB12-20145P (HLX04-O), a recombinant anti-VEGF humanised monoclonal antibody injection jointly developed by the Group and Shanghai Henlius Biotech, Inc. more info >> |
|
|
亿胜生物宣布贝伐珠单抗眼科适应症国际多中心III期临床研究完成美国首例患者给药 |
| 亿胜生物科技有限公司（“亿胜生物”或“集团”，股票代码：1061.HK）今日宣布，集团与上海复宏汉霖生物技术股份有限公司（“复宏汉霖”，股票代码：2696.HK）合作开发重组抗血管内皮生长因子（Vascular endothelial growth factor，VEGF）人源化单克隆抗体注射液EB12-20145P（HLX04-O）的国际多中心III期临床研究（NCT04740671）完成美国首例患者给药 more info >> |
|
|
億勝生物宣佈貝伐珠單抗眼科適應症國際多中心III期臨床研究完成美國首例患者給藥 |
| 億勝生物科技有限公司（「億勝生物」或「集團」，股票代碼：1061.HK）今日宣佈，集團與上海復宏漢霖生物技術股份有限公司（「復宏漢霖」，股票代碼：2696.HK）合作開發重組抗血管內皮生長因子（Vascular endothelial growth factor，VEGF）人源化單克隆抗體注射液EB12-20145P（HLX04-O）的國際多中心III期臨床研究（NCT04740671）完成美國首例患者給葯 more info >> |
|
| Thursday, October 13, 2022 |
|
|
Essex Biotechnology Secures Exclusive Rights and Interests in SkQ1 for Ophthalmology from Mitotech |
| Essex Bio-Technology Ltd (Essex Bio-Technology; HKG: 1061) wishes to announce that wholly-owned subsidiary Essex Bio-Investment Ltd (Essex Bioinvestment) on 13 October 2022 successfully secured (i) a patent and know-how licence agreement; and (ii) a patent assignment deed in relation to SkQ1, an active pharmaceutical ingredient, from Mitotech S.A. more info >> |
|
|
亿胜生物成功从Mitotech获得SkQ1眼科领域全球独家权益 |
| 亿胜生物科技有限公司（“亿胜生物”，连同其附属公司统称“本集团”）欣然宣布，本集团全资附属公司Essex Bio-Investment Limited（“Essex Bio-Investment”）与Mitotech S.A.（“Mitotech”）已于2022年10月13日订立与SkQ1（一种活性药物成分）相关的(i)专利及专有技术许可协议及(ii)专利转让契据，二者统称“协议”。 more info >> |
|
|
億勝生物成功從Mitotech獲得SkQ1眼科領域全球獨家權益 |
| 億勝生物科技有限公司（「億勝生物」，連同其附屬公司統稱「本集團」）欣然宣佈，本集團全資附屬公司Essex Bio-Investment Limited（「Essex Bio-Investment」）與Mitotech S.A.（「Mitotech」）已於2022年10月13日訂立與SkQ1（一種活性藥物成分）相關的(i)專利及專有技術許可協議及(ii)專利轉讓契據，二者統稱「協議」。 more info >> |
|
| Tuesday, August 16, 2022 |
|
|
亿胜生物荣登「2022年福布斯亚洲中小上市企业200强」 |
| 亿胜生物科技有限公司（「亿胜生物」或「集团」，股票代码：1061.HK）欣然宣布，凭借在多项指标上所彰显的杰出可持续发展能力，集团荣登「2022年福布斯亚洲中小上市企业200强」榜单。 more info >> |
|
|
億勝生物榮登「2022年福布斯亞洲中小上市企業200強」 |
| 億勝生物科技有限公司（「億勝生物」或「集團」，股票代碼：1061.HK）欣然宣佈，憑藉在多項指標上所彰顯的傑出可持續發展能力，集團榮登「2022年福布斯亞洲中小上市企業200強」榜單。 more info >> |
|
|
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022" |
| Essex Bio-Technology Ltd ("EssexBio" or the "Group", Stock Code: 1061.HK) is pleased and honoured to announce that it is included in "Forbes Asia's 200 Best Under A Billion 2022" - for the Group's outstanding long-term sustainable development across a variety of metrics. more info >> |
|
|
|
|
